Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology.

Alexander SPH, Roberts RE, Broughton BRS, Sobey CG, George CH, Stanford SC, Cirino G, Docherty JR, Giembycz MA, Hoyer D, Insel PA, Izzo AA, Ji Y, MacEwan DJ, Mangum J, Wonnacott S, Ahluwalia A.

Br J Pharmacol. 2018 Feb;175(3):407-411. doi: 10.1111/bph.14112. No abstract available.

PMID:
29350411
2.

New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome.

Wilson LJ, Linley A, Hammond DE, Hood FE, Coulson JM, MacEwan DJ, Ross SJ, Slupsky JR, Smith PD, Eyers PA, Prior IA.

Cancer Res. 2018 Jan 1;78(1):15-29. doi: 10.1158/0008-5472.CAN-17-2291. Epub 2017 Dec 18. Review.

PMID:
29254998
3.

Updating the guidelines for data transparency in the British Journal of Pharmacology - data sharing and the use of scatter plots instead of bar charts.

George CH, Stanford SC, Alexander S, Cirino G, Docherty JR, Giembycz MA, Hoyer D, Insel PA, Izzo AA, Ji Y, MacEwan DJ, Sobey CG, Wonnacott S, Ahluwalia A.

Br J Pharmacol. 2017 Sep;174(17):2801-2804. doi: 10.1111/bph.13925. No abstract available.

PMID:
28801996
4.

Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells.

Rushworth SA, Pillinger G, Abdul-Aziz A, Piddock R, Shafat MS, Murray MY, Zaitseva L, Lawes MJ, MacEwan DJ, Bowles KM.

Lancet Haematol. 2015 May;2(5):e204-11. doi: 10.1016/S2352-3026(15)00046-0. Epub 2015 Apr 14.

PMID:
26688095
5.

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.

Pillinger G, Abdul-Aziz A, Zaitseva L, Lawes M, MacEwan DJ, Bowles KM, Rushworth SA.

Sci Rep. 2015 Aug 21;5:12949. doi: 10.1038/srep12949.

6.

TWEAKing for a fight with GVHD.

MacEwan DJ.

Blood. 2015 Jul 23;126(4):429-30. doi: 10.1182/blood-2015-06-649517.

7.

Experimental design and analysis and their reporting: new guidance for publication in BJP.

Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA, Gilchrist A, Hoyer D, Insel PA, Izzo AA, Lawrence AJ, MacEwan DJ, Moon LD, Wonnacott S, Weston AH, McGrath JC.

Br J Pharmacol. 2015 Jul;172(14):3461-71. doi: 10.1111/bph.12856. No abstract available.

8.

Epigenetics and pharmacology.

Stefanska B, MacEwan DJ.

Br J Pharmacol. 2015 Jun;172(11):2701-4. doi: 10.1111/bph.13136.

9.

Oxidative stress responses and NRF2 in human leukaemia.

Abdul-Aziz A, MacEwan DJ, Bowles KM, Rushworth SA.

Oxid Med Cell Longev. 2015;2015:454659. doi: 10.1155/2015/454659. Epub 2015 Mar 30. Review.

10.

Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.

Murray MY, Zaitseva L, Auger MJ, Craig JI, MacEwan DJ, Rushworth SA, Bowles KM.

Cell Cycle. 2015;14(14):2367-75. doi: 10.1080/15384101.2014.998067. Epub 2015 Jan 7.

11.

Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML.

Zaitseva L, Murray MY, Shafat MS, Lawes MJ, MacEwan DJ, Bowles KM, Rushworth SA.

Oncotarget. 2014 Oct 30;5(20):9930-8.

12.

Understanding life and death decisions in human leukaemias.

MacEwan DJ, Barrera LN, Keadsanti S, Rushworth SA, Shah NM, Yuan T, Zaitseva L.

Biochem Soc Trans. 2014 Aug;42(4):747-51. doi: 10.1042/BST20140127.

PMID:
25109952
13.

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.

Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ.

Blood. 2014 Feb 20;123(8):1229-38. doi: 10.1182/blood-2013-06-511154. Epub 2013 Dec 4.

14.

Ibrutinib in relapsed chronic lymphocytic leukemia.

Rushworth SA, MacEwan DJ, Bowles KM.

N Engl J Med. 2013 Sep 26;369(13):1277-8. doi: 10.1056/NEJMc1309710#SA2. No abstract available.

PMID:
24066760
15.

Understanding the role of NRF2-regulated miRNAs in human malignancies.

Shah NM, Rushworth SA, Murray MY, Bowles KM, MacEwan DJ.

Oncotarget. 2013 Aug;4(8):1130-42. Review.

16.

Emerging therapeutic aspects in oncology.

Macewan DJ.

Br J Pharmacol. 2013 Aug;169(8):1647-51. doi: 10.1111/bph.12304.

17.

Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression.

Murray MY, Rushworth SA, Zaitseva L, Bowles KM, Macewan DJ.

Cell Cycle. 2013 Jul 1;12(13):2144-53. doi: 10.4161/cc.25251. Epub 2013 Jun 11.

18.

The high Nrf2 expression in human acute myeloid leukemia is driven by NF-κB and underlies its chemo-resistance.

Rushworth SA, Zaitseva L, Murray MY, Shah NM, Bowles KM, MacEwan DJ.

Blood. 2012 Dec 20;120(26):5188-98. doi: 10.1182/blood-2012-04-422121. Epub 2012 Oct 17.

19.

BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.

Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ.

Cell Signal. 2013 Jan;25(1):106-12. doi: 10.1016/j.cellsig.2012.09.008. Epub 2012 Sep 11.

PMID:
22975686
20.

Bortezomib induces heme oxygenase-1 expression in multiple myeloma.

Barrera LN, Rushworth SA, Bowles KM, MacEwan DJ.

Cell Cycle. 2012 Jun 15;11(12):2248-52. doi: 10.4161/cc.20343. Epub 2012 Jun 15.

Supplemental Content

Loading ...
Support Center